Table 2 Medications and immunosuppression (n = 336)
Medication/immunosuppression | 6 months n (%) | 12 months n (%) | P value |
|---|---|---|---|
Mycophenolate dose < 1.5 g/day | 70 (20.8) | 107 (31.8) | < 0.001 |
Calcineurin inhibitor: | |||
Tacrolimus | 329 (97.9) | 325 (96.7) | 0.13b |
Cyclosporine | 4 (1.2) | 8 (2.4) | |
None | 3 (0.9) | 3 (0.9) | |
Sirolimus/everolimus | 11 (3.3) | 7 (2.1) | 0.13b |
Prednisolonea | 6.9 (2.6) | 5.3 (1.5) | < 0.001 |
Plasma exchange | 18 (5.4) | 8 (2.4) | 0.041 |
Intravenous immunoglobulin | 49 (14.6) | 28 (8.3) | 0.006 |
Proton pump inhibitor | 301 (89.6) | 287 (85.4) | 0.006 |
Trimethoprim-sulfamethoxazole | 301 (89.6) | 256 (76.2) | < 0.001 |
Valganciclovir | 180 (53.4) | 51 (15.2) | < 0.001 |
Renin-angiotensin inhibitor | 49 (14.6) | 60 (17.9) | 0.055 |
Anticoagulation | |||
None | 239 (71.1) | 238 (70.8) | 1.00b |
Aspirin | 82 (24.4) | 78 (23.2) | |
Clopidogrel | 2 (0.6) | 2 (0.6) | |
Dual antiplatelets | 1 (0.3) | 2 (0.6) | |
Warfarin | 8 (2.4) | 10 (3.0) | |
Novel anticoagulants | 4 (1.2) | 6 (1.8) | |
Iron supplementation | |||
None | 321 (95.5) | 322 (95.8) | 1.00b |
Oral | 7 (2.1) | 8 (2.4) | |
Intravenous | 8 (2.4) | 6 (1.8) | |
Erythropoiesis-stimulating agent | 58 (17.3) | 28 (8.3) | < 0.001 |
B12 injections | 7 (2.1) | 6 (1.8) | 0.77b |